ReviewMovement disorders : official journal of the Movement Disorder Society2015
The therapeutic potential of cannabinoids for movement disorders.
Review in Movement disorders : official journal of the Movement Disorder Society, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03639064 (A Phase II, Randomized, Open-label, Double-blind, Two-center Study to Evaluate the Tolerability, Safety and Dose-finding of Oil Cannabis Preparation for Pain in Parkinson's Disease), which is not on this map. Cited by 43 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase II, Randomized, Open-label, Double-blind, Two-center Study to Evaluate the Tolerability, Safety and Dose-finding of Oil Cannabis Preparation for Pain in Parkinson's Disease
Who cites it
43 citing papers in PubMed, 2 syntheses or guidelines pooled it, 120 citations in OpenAlex.
- Randomized controlled trials on the use of cannabis-based medicines in movement disorders: a systematic review.Journal of neural transmission (Vienna, Austria : 1996) · 2022Pooled it
- Cannabis in the Treatment of Dystonia, Dyskinesias, and Tics.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2015Pooled it
- Medical cannabis oil for benign essential blepharospasm: a prospective, randomized controlled pilot study.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2022Trial
- Non-Motor Symptoms in Parkinson's Disease are Reduced by Nabilone.Annals of neurology · 2020Trial
- Nabilone for non-motor symptoms of Parkinson's disease: a randomized placebo-controlled, double-blind, parallel-group, enriched enrolment randomized withdrawal study (The NMS-Nab Study).Journal of neural transmission (Vienna, Austria : 1996) · 2019Trial
- A double-blind, randomized, cross-over, placebo-controlled, pilot trial with Sativex in Huntington's disease.Journal of neurology · 2016Trial
- The endocannabinoid system and the ageing brain.Nature reviews. Neuroscience · 2026Review
- Evidence and Tradition in Dialogue: Biological Sex Variability in Phytomedicine Research as a Foundation for Safety, Efficacy, and Robust Evidence Standards.Medicines (Basel, Switzerland) · 2026Review
- Sustained Reduction of Dystonic Tremor and Pain after Cannabis Oil Administration and Physiotherapy in Thalamic Ischemia: A One-Year Case Report.Current neuropharmacology · 2026Article
- Ratio of excitatory and inhibitory synaptic processes in periaqueductal gray matter of the brain activated by the raphe magnus nucleus in a model of Parkinson's disease with hydrocortisone protection.The Korean journal of pain · 2025Article
- Diet and Nutrients in Rare Neurological Disorders: Biological, Biochemical, and Pathophysiological Evidence.Nutrients · 2024Review
- Long-term safety and efficacy of open-label nabilone on sleep and pain in Parkinson´s Disease.NPJ Parkinson's disease · 2024Article
- Parkinson disease psychosis: from phenomenology to neurobiological mechanisms.Nature reviews. Neurology · 2024Review
- Therapeutic use of medical Cannabis in neurological diseases: a clinical update.Journal of neural transmission (Vienna, Austria : 1996) · 2024Review
- A Phase Ib, Double Blind, Randomized Study of Cannabis Oil for Pain in Parkinson's Disease.Movement disorders clinical practice · 2023Article
- Driving Impairment in Movement Disorders.Movement disorders clinical practice · 2023Review
- A single-center real-life study on the use of medical cannabis in patients with dystonia.Frontiers in neurology · 2023Article
- Article
- Receptor-Dependent and Independent Regulation of Voltage-Gated CaInternational journal of molecular sciences · 2021Review
- Therapeutic Attributes of Endocannabinoid System against Neuro-Inflammatory Autoimmune Disorders.Molecules (Basel, Switzerland) · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
There is growing interest in the therapeutic potential of marijuana (cannabis) and cannabinoid-based chemicals within the medical community and, particularly, for neurological conditions. This interest is driven both by changes in the legal status of cannabis in many areas and increasing research into the roles of endocannabinoids within the central nervous system and their potential as symptomatic and/or neuroprotective therapies. We review basic science as well as preclinical and clinical studies on the therapeutic potential of cannabinoids specifically as it relates to movement disorders. The pharmacology of cannabis is complex, with over 60 neuroactive chemicals identified to date. The endocannabinoid system modulates neurotransmission involved in motor function, particularly within the basal ganglia. Preclinical research in animal models of several movement disorders have shown variable evidence for symptomatic benefits, but more consistently suggest potential neuroprotective effects in several animal models of Parkinson's (PD) and Huntington's disease (HD). Clinical observations and clinical trials of cannabinoid-based therapies suggests a possible benefit of cannabinoids for tics and probably no benefit for tremor in multiple sclerosis or dyskinesias or motor symptoms in PD. Data are insufficient to draw conclusions regarding HD, dystonia, or ataxia and nonexistent for myoclonus or RLS. Despite the widespread publicity about the medical benefits of cannabinoids, further preclinical and clinical research is needed to better characterize the pharmacological, physiological, and therapeutic effects of this class of drugs in movement disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.